Crossmark

Superior Bioavailability of a Novel 1.5% Ashwagandha Formulation (Zenroot™): A Randomized, Double-Blind, Single-Dose, Comparative, Oral Bioavailability Study in Healthy Adults

Crossref DOI link: https://doi.org/10.1007/s12325-025-03292-7

Published Online: 2025-08-01

Published Print: 2025-10

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Ramapalaniappan, Abiraamasundari

Loganathan, Vijayakrishnan

Morde, Abhijeet

Padigaru, Muralidhara

Patni, Paras

Joshua, Lincy

Thomas, Jestin V.
License Information

Text and Data Mining valid from 2025-08-01

Version of Record valid from 2025-08-01
More Information

Article History

Received: 9 April 2025

Accepted: 20 June 2025

First Online: 1 August 2025

Declarations

:

: Muralidhara Padigaru, Abhijeet Morde, and Paras Patni are employees of OmniActive Health Technologies Limited. R Abiraamasundari, L Vijayakrishnan, Lincy Joshua, and Jestin V. Thomas declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

: Institutional ethics approval was obtained from ‘The Research Ethics Committee’ Coimbatore, India. This study was conducted in compliance with the ethical principles originating in or derived from the Declaration of Helsinki and in compliance with the International Conference on Harmonization (ICH), Good Clinical Practice (GCP) Guidelines, as well as in strict compliance with the “The New Drugs and Clinical Trial Rules- 2019”, the Ministry of Health and Family Welfare and the Government of India at all stages of the trial for adherence to protocol and compliance with ethical and regulatory guidelines. Voluntary consent was obtained in written from all the study participants before commencing any study related activities. The EC was duly apprised of the progress and updates of the trial at regular intervals as per prescribed guidelines.

Document is current

Any future updates will be listed below